A

Atea Pharmaceuticals
D

AVIR

3.09000
USD
-0.05
(-1.59%)
مغلق
حجم التداول
11,817
الربح لكل سهم
0
العائد الربحي
-
P/E
-1
حجم السوق
260,990,852
نظرة عامةالتوصياتالأفكار والتحليلاتالأخبار
أصول ذات صلة
    A
    ABUS
    -0.01500
    (-0.44%)
    3.42500 USD
    A
    ADAP
    -0.01800
    (-3.11%)
    0.56000 USD
    A
    ASND
    -2.390
    (-1.54%)
    152.440 USD
    C
    CRNC
    -0.900
    (-6.69%)
    12.560 USD
    G
    GERN
    -0.05500
    (-2.10%)
    2.57000 USD
    I
    ICHR
    -0.970
    (-2.81%)
    33.560 USD
    N
    NVAX
    0.05500
    (0.69%)
    7.98000 USD
    X
    XENE
    0.410
    (1.04%)
    39.690 USD
    المزيد
الأخبار
المقالات

العنوان: Atea Pharmaceuticals

القطاع: Healthcare
الصناعة: Biotechnology
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).